Allos Therapeutics Inc. said it expects to net about $56.6 million from a public offering of 10.8 million shares of common stock priced at $5.64 per share, the proceeds of which will help fund clinical trials of the company's lymphoma product. (BioWorld Today)

The attraction of Japanese pharmaceutical companies for biotech continued Wednesday with the announcement that Daiichi Sankyo Co. Ltd. is buying privately held U3 Pharma AG, a German biotechnology company, for $235 million. (BioWorld Today)